SLDB Stock Overview
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Solid Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.34 |
| 52 Week High | US$15.05 |
| 52 Week Low | US$1.81 |
| Beta | 1.94 |
| 1 Month Change | -10.55% |
| 3 Month Change | 32.90% |
| 1 Year Change | 60.56% |
| 3 Year Change | -84.47% |
| 5 Year Change | -88.85% |
| Change since IPO | -96.95% |
Recent News & Updates
Buy Solid Biosciences: Unpacking Its Main Value Driver
Apr 10Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
Jan 17Recent updates
Buy Solid Biosciences: Unpacking Its Main Value Driver
Apr 10Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
Jan 17Solid Biosciences to acquire gene therapy company AavantiBio
Sep 30Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results
Apr 30
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates
Apr 28We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Mar 17Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans
Oct 28We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Jul 13We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely
Mar 17Soild Bio sinks 13% after Sarepta data misses goal
Jan 08Solid Biosciences launches $90M private placement
Dec 11Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data
Nov 10Shareholder Returns
| SLDB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | 0.5% | 2.7% |
| 1Y | 60.6% | 3.4% | 26.0% |
Return vs Industry: SLDB exceeded the US Biotechs industry which returned 3% over the past year.
Return vs Market: SLDB exceeded the US Market which returned 25% over the past year.
Price Volatility
| SLDB volatility | |
|---|---|
| SLDB Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLDB's share price has been volatile over the past 3 months.
Volatility Over Time: SLDB's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 88 | Bo Cumbo | www.solidbio.com |
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich’s ataxia, as well as other drugs for the treatment of cardiac and other diseases.
Solid Biosciences Inc. Fundamentals Summary
| SLDB fundamental statistics | |
|---|---|
| Market cap | US$388.07m |
| Earnings (TTM) | -US$96.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.1x
P/E RatioIs SLDB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLDB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$76.56m |
| Gross Profit | -US$76.56m |
| Other Expenses | US$19.45m |
| Earnings | -US$96.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLDB perform over the long term?
See historical performance and comparison